BioCentury | Jan 16, 2014
Targets & Mechanisms

Putting a lid on cancer cell proteasomes

Blocking the catalytic activity of proteasomes is a tried-and-true strategy in multiple myeloma, but use of marketed inhibitors is limited by drug resistance and lack of efficacy in solid tumors. Now, a team from The...
BioCentury | May 31, 2010
Company News

Genomic Vision management update

Genomic Vision S.A. , Paris, France Business: Genomics, Diagnostic Hired: Erwan Martin as CFO, formerly CFO and an executive director at Cytomics Pharmaceuticals WIR Staff Diagnostic...
BioCentury | May 5, 2008
Company News

Cytomics board of directors update

Cytomics Pharmaceuticals , Orsay, France Business: Cancer, Infectious Appointed: Martine George, SVP of drug development and CMO of GPC Biotech AG WIR Staff cancer Infectious...
BioCentury | Jun 4, 2007
Company News

Cytomics Systems board of directors update

Cytomics Systems , Gif-sur-Yvette Cedex, France Business: Infectious, Cancer, High throughput screening Appointed: Gilles Brisson, formerly chairman of sanofi-aventis Group 's Aventis Pharma S.A. subsidiary WIR Staff...
BioCentury | Mar 5, 2007
Company News

Cytomics Systems board of directors update

Cytomics Systems , Gif-sur-Yvette Cedex, France Business: Infectious, Cancer, High throughput screening Appointed: Thierry Hercend, formerly VP and head of oncology research at sanofi-aventis Group , as chairman WIR Staff cancer Infectious...
BioCentury | Mar 5, 2007
Company News

Cytomics Systems management update

Cytomics Systems , Gif-sur-Yvette Cedex, France Business: Infectious, Cancer, High throughput screening Hired: Bernard Cambou as CEO, formerly CEO of StageMark Inc.; he replaces Dominique Thomas WIR Staff...
BioCentury | Feb 28, 2006
Financial News

Cytomics raises EUR 10 million

Cytomics (Gif sur Yvette, France) raised EUR 10 million ($11.9 million) in a series B round led by Edmond de Rothschild and Truffle Venture. Existing investor SGAM Alternative Investments also participated in the round. Aelios...
BioCentury | Feb 27, 2006
Tools & Techniques

Better ubiquitin screening

The ubiquitin proteasome pathway is involved in many cell processes, including apoptosis, immune response, cell cycle progression, gene expression regulation and DNA repair. But its complexity makes it difficult to build assays to gauge the...
BioCentury | Dec 20, 2004
Clinical News

Cytomics Systems preclinical data

In a mouse model of pathogenic fungus infection, a single dose treatment with CC 0105 resulted in a complete cure with no undesirable side effects. Cytomics Systems , Gif-sur-Yvette Cedex, France Product: CC 0105 Indication: Treat...
BioCentury | Dec 20, 2004
Clinical News

Cytomics Systems preclinical data

In a mouse model of pathogenic fungus infection, a single dose treatment of CYD 1274 resulted in complete cure with no undesirable side effects. Cytomics Systems , Gif-sur-Yvette Cedex, France Product: CYD 1274 Indication: Treat fungal...
Items per page:
1 - 10 of 32
BioCentury | Jan 16, 2014
Targets & Mechanisms

Putting a lid on cancer cell proteasomes

Blocking the catalytic activity of proteasomes is a tried-and-true strategy in multiple myeloma, but use of marketed inhibitors is limited by drug resistance and lack of efficacy in solid tumors. Now, a team from The...
BioCentury | May 31, 2010
Company News

Genomic Vision management update

Genomic Vision S.A. , Paris, France Business: Genomics, Diagnostic Hired: Erwan Martin as CFO, formerly CFO and an executive director at Cytomics Pharmaceuticals WIR Staff Diagnostic...
BioCentury | May 5, 2008
Company News

Cytomics board of directors update

Cytomics Pharmaceuticals , Orsay, France Business: Cancer, Infectious Appointed: Martine George, SVP of drug development and CMO of GPC Biotech AG WIR Staff cancer Infectious...
BioCentury | Jun 4, 2007
Company News

Cytomics Systems board of directors update

Cytomics Systems , Gif-sur-Yvette Cedex, France Business: Infectious, Cancer, High throughput screening Appointed: Gilles Brisson, formerly chairman of sanofi-aventis Group 's Aventis Pharma S.A. subsidiary WIR Staff...
BioCentury | Mar 5, 2007
Company News

Cytomics Systems board of directors update

Cytomics Systems , Gif-sur-Yvette Cedex, France Business: Infectious, Cancer, High throughput screening Appointed: Thierry Hercend, formerly VP and head of oncology research at sanofi-aventis Group , as chairman WIR Staff cancer Infectious...
BioCentury | Mar 5, 2007
Company News

Cytomics Systems management update

Cytomics Systems , Gif-sur-Yvette Cedex, France Business: Infectious, Cancer, High throughput screening Hired: Bernard Cambou as CEO, formerly CEO of StageMark Inc.; he replaces Dominique Thomas WIR Staff...
BioCentury | Feb 28, 2006
Financial News

Cytomics raises EUR 10 million

Cytomics (Gif sur Yvette, France) raised EUR 10 million ($11.9 million) in a series B round led by Edmond de Rothschild and Truffle Venture. Existing investor SGAM Alternative Investments also participated in the round. Aelios...
BioCentury | Feb 27, 2006
Tools & Techniques

Better ubiquitin screening

The ubiquitin proteasome pathway is involved in many cell processes, including apoptosis, immune response, cell cycle progression, gene expression regulation and DNA repair. But its complexity makes it difficult to build assays to gauge the...
BioCentury | Dec 20, 2004
Clinical News

Cytomics Systems preclinical data

In a mouse model of pathogenic fungus infection, a single dose treatment with CC 0105 resulted in a complete cure with no undesirable side effects. Cytomics Systems , Gif-sur-Yvette Cedex, France Product: CC 0105 Indication: Treat...
BioCentury | Dec 20, 2004
Clinical News

Cytomics Systems preclinical data

In a mouse model of pathogenic fungus infection, a single dose treatment of CYD 1274 resulted in complete cure with no undesirable side effects. Cytomics Systems , Gif-sur-Yvette Cedex, France Product: CYD 1274 Indication: Treat fungal...
Items per page:
1 - 10 of 32